This activity is sponsored by PTCE and supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Speaker: Kirollos S. Hanna, PharmD, BCPS, BCOP, M Health Fairview and Mayo Clinic College of Medicine
Program Description
B-cell malignancies are a heterogenous group of cancers impacting B lymphocytes and include most non-Hodgkin lymphomas, such as mantle cell lymphoma, as well as chronic lymphocytic leukemia and Waldenström macroglobulinemia. As multiple oral BTK inhibitors are currently available, it is necessary for professionals involved in dispensing and administering agents for patients with cancer to be aware of expanding approved indications as well as the latest clinical and safety data. Patient- and disease-specific factors, in addition to medication-specific nuances, must be considered to ensure individualized and appropriate management of patients receiving BTK inhibitors. This session will review the appropriate place in therapy for the BTK inhibitors along with strategies oncology professionals can use in improving medication adherence.
Target Audience: Oncology pharmacists, pharmacy technicians, physicians, and nurses
Type of Activity: Knowledge
Educational Objectives:
At the completion of this activity, pharmacists, physicians, and nurses will be able to:
• Describe the relationship between BTK and the BCR pathway in B-cell malignancies
• Review guideline recommendations for the use of BTK inhibitors in the management of mantle cell lymphoma, chronic lymphocytic leukemia/small cell leukemia, Waldenström macroglobulinemia, and marginal zone lymphoma
• Outline a strategy to improve medication adherence among patients receiving a BTK inhibitor
At the completion of this activity, pharmacy technicians will be able to:
• Describe the rationale for use of BTK inhibitors in the treatment of B-cell malignancies
• Review appropriate place in therapy for BTK inhibitors in the management of B-cell malignancies
• Outline a strategy to assist in promoting medication adherence in patients receiving a BTK inhibitor
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (1.0 CEU) under the ACPE universal activity numbers 0290-0000-20-256-L01-P and 0290-0000-20-256-L01-T. The activity is available for CE credit on October 23, 2020.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education
(ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education™.
Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 3 Contact Hours. Instructions for Completing the Activity and Receiving CPE Credit to receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation.
After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. Credit must be requested no later than December 23, 2020. CE credit will not be issued after this date.